dabigatran has been researched along with sphingosine in 2 studies
Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (sphingosine) | Trials (sphingosine) | Recent Studies (post-2010) (sphingosine) |
---|---|---|---|---|---|
3,887 | 261 | 3,490 | 8,325 | 117 | 3,459 |
Protein | Taxonomy | dabigatran (IC50) | sphingosine (IC50) |
---|---|---|---|
ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | 6.3125 | |
cAMP-dependent protein kinase catalytic subunit alpha | Rattus norvegicus (Norway rat) | 0.098 | |
Sphingosine kinase 2 | Homo sapiens (human) | 1.56 | |
Sphingosine kinase 1 | Homo sapiens (human) | 3.86 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hussar, DA | 1 |
Furberg, CD; Moore, TJ | 1 |
2 other study(ies) available for dabigatran and sphingosine
Article | Year |
---|---|
New drugs 2011 part 2.
Topics: Benzimidazoles; Contraceptives, Postcoital; Dabigatran; Drug Therapy; Fibrinolytic Agents; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Norpregnadienes; Pharmaceutical Preparations; Propylene Glycols; Pyridines; Sphingosine | 2011 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |